Advertisement News Archives - Page 410 of 5171 - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

November 6, 2024

Insignis Therapeutics’ IN-001 clinical programme receives positive FDA response

Insignis Therapeutics has received a positive response from the US Food and Drug Administration (FDA) on IN-001 clinical programme for needle-free anaphylaxis treatment.

Insignis Therapeutics’ IN-001 clinical programme receives positive FDA response